{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:41:05Z","timestamp":1781620865433,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00277-021-04594-w","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T06:02:20Z","timestamp":1627279340000},"page":"2541-2546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-8778","authenticated-orcid":false,"given":"Marta","family":"Krejci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Sandecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Sevcikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krejci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Knechtova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Kral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"4594_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/ejh.13502","volume":"105","author":"KH Susek","year":"2020","unstructured":"Susek KH, Gran Ch, Ljunggren HG et al (2020) Outcome of COVID-19 in multiple myeloma patients in relation to treatment. Eur J Hematology 105:751\u2013754","journal-title":"Eur J Hematology"},{"key":"4594_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"312","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM (2020) Characteristics of and important lessions from the coronarovirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases the Chinese Center for Disease Control and Prevention. JAMA 312:1239\u20131242","journal-title":"JAMA"},{"key":"4594_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Yu et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708\u20131720","journal-title":"N Engl J Med"},{"key":"4594_CR4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai M, Liu D, Liu M et al (2020) Patients with cancer appear more vulnerable for SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 10:783\u2013791","journal-title":"Cancer Discov"},{"key":"4594_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/cid\/ciaa863","volume":"72","author":"M Fung","year":"2021","unstructured":"Fung M, Babik JM (2021) COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 72:340\u2013350","journal-title":"Clin Infect Dis"},{"key":"4594_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F et al (2020) Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323:1582\u20131589","journal-title":"JAMA"},{"key":"4594_CR7","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagan N, Shin D et al (2020) Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 382:2327\u20132336","journal-title":"N Engl J Med"},{"key":"4594_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","volume":"32","author":"JLJ Heaney","year":"2018","unstructured":"Heaney JLJ, Campbell JP, Iqbal G et al (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia 32:1727\u20131738","journal-title":"Leukemia"},{"key":"4594_CR9","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/blood.2020008150","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari A, Samur MK, Martinez-Lopez J et al (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from International Myeloma Society data set. Blood 136:3033\u20133040","journal-title":"Blood"},{"issue":"12","key":"4594_CR10","doi-asserted-by":"publisher","first-page":"e0188988","DOI":"10.1371\/journal.pone.0188988","volume":"12","author":"R Sorrig","year":"2017","unstructured":"Sorrig R, Klaussen TW, Salomo M et al (2017) Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population. Plos One 12(12):e0188988","journal-title":"Plos One"},{"key":"4594_CR11","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","volume":"32","author":"JLJ Heaney","year":"2018","unstructured":"Heaney JLJ, Cambell JP, Iqbal G et al (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia 32:1727\u20131738","journal-title":"Leukemia"},{"key":"4594_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandian","year":"2016","unstructured":"Kazandian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Seminar Oncol 43:676\u2013681","journal-title":"Seminar Oncol"},{"key":"4594_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blinmark","year":"2015","unstructured":"Blinmark C, Holmberg E, Mellqvist UH et al (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100:107\u2013113","journal-title":"Haematologica"},{"key":"4594_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","volume":"34","author":"E Terpos","year":"2020","unstructured":"Terpos E, Engelhardt M, Cook G et al (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 34:2000\u20132011","journal-title":"Leukemia"},{"key":"4594_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.blre.2014.01.004","volume":"28","author":"BW Teh","year":"2014","unstructured":"Teh BW, Harrison SJ, Pellegrini M et al (2014) Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev 28:75\u201386","journal-title":"Blood Rev"},{"key":"4594_CR16","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG et al (2005) International Staging System for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"4594_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"4594_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"M Oken","year":"1982","unstructured":"Oken M, Creech R, Tormey D et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"4594_CR19","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gorg IY, Fox TA et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136:2881\u20132892","journal-title":"Blood"},{"key":"4594_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","volume":"97","author":"M Chen","year":"2018","unstructured":"Chen M, Zhao Y, Xu C et al (2018) Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol 97:925\u2013944","journal-title":"Ann Hematol"},{"key":"4594_CR21","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","volume":"183","author":"M Basler","year":"2009","unstructured":"Basler M, Lauer C, Beck U et al (2009) The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 183:6145\u20136150","journal-title":"J Immunol"},{"key":"4594_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","volume":"13","author":"B Wang","year":"2020","unstructured":"Wang B, Van Oekelen O, Mouhieddine TH et al (2020) A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol 13:94","journal-title":"J Hematol Oncol"},{"key":"4594_CR23","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1111\/bjh.16874","volume":"190","author":"G Cook","year":"2020","unstructured":"Cook G, Ashcroft A, Pratt G et al (2020) Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic and anti-cancer therapy. Br J Haematol 190:e83\u2013e86","journal-title":"Br J Haematol"},{"key":"4594_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/ejh.13190","volume":"102","author":"R Sorrig","year":"2019","unstructured":"Sorrig R, Klausen TW, Salomo M et al (2019) Risk factors for infections in newly diagnosed multiple myeloma patients: a Danish retrospective nationwide cohort study. Eur J Hematol 102:182\u2013190","journal-title":"Eur J Hematol"},{"key":"4594_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","volume":"10","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez J, Mateos MV, Encinas C et al (2020) Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J 10:103","journal-title":"Blood Cancer J"},{"key":"4594_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.abc3517","volume":"369","author":"H Salje","year":"2020","unstructured":"Salje H, Tran KC, Lefrancq N et al (2020) Estimating the burden of SARS-Cov-2 in France. Science 369:208\u2013211","journal-title":"Science"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04594-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04594-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04594-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:54:37Z","timestamp":1672923277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04594-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4594"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04594-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}